Skip to main content

Table 15 (abstract P215). Follow-up effectiveness

From: Proceedings of the 23rd Paediatric Rheumatology European Society Congress: part two

Endpoints

Baseline

n = 308

3 months

n = 247

6 months

n = 215

12 months

n = 121

24 months

n = 35

Clinical

MD Global

1.9/1.0

1.46/1.0

1.49/0.5

1.13/0.5

0.89/0.5

CID,1%

33

32

38

50

37

JAMAR Functional2

5.4/3.0

4.8/3.0

4.3/2.0

3.6/0.5

2.7/2.0

JAMAR HRQoL

6.9/6.0

6.0/5.0

5.6/4.0

4.9/3.0

5.1/4.0

  1. Data are mean/median unless otherwise indicated
  2. CID clinical inactive disease (Wallace criteria), JAMAR Functional Juvenile Arthritis Multidimensional Assessment Report Functionality Scale Child (range 0–15), JAMAR HRQoL Juvenile Arthritis Multidimensional Assessment Report HRQoL Scale Child (range 0–15), MD Global MD Global Disease Activity (VAS 0–10), VAS visual analog scale
  3. 1. Wallace C, et al. Arthritis Care Res 2011;63:929–36.
  4. 2. Filocamo G, et al. J Rheumatol 2011;38:938–53.
Back to article page

Pediatric Rheumatology

ISSN: 1546-0096